Rilzabrutinib (BTK Inhibitor)
Immune Thrombocytopenia (ITP)
Sponsor Sanofi
300 Enrollment Target
85 Trial Sites
5 Countries
December 2026 Est. Completion
About This Trial
Oral reversible BTK inhibitor for chronic ITP patients.
Primary Endpoints
- Durable platelet response
- Reduction in bleeding events
Latest Update
February 2026
Phase 2 showed 50% durable response rate. Potential first oral therapy for ITP.